{"id":"vedolizumab-iv","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Nasopharyngitis"},{"rate":"8–12","effect":"Headache"},{"rate":"5–10","effect":"Arthralgia"},{"rate":"5–8","effect":"Pyrexia"},{"rate":"5–8","effect":"Fatigue"},{"rate":"2–4","effect":"Infections (serious)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to α4β7 integrin expressed on memory T cells, vedolizumab prevents these cells from adhering to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on gut endothelial cells. This selective gut-homing mechanism reduces intestinal inflammation while minimizing systemic immunosuppression, making it effective for inflammatory bowel diseases.","oneSentence":"Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on gut-homing lymphocytes, preventing their migration to the gastrointestinal tract.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:04.861Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe ulcerative colitis"},{"name":"Moderate to severe Crohn's disease"}]},"trialDetails":[{"nctId":"NCT06581328","phase":"PHASE4","title":"A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-27","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":400},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT06095128","phase":"PHASE4","title":"A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-06-12","conditions":"Ulcerative Colitis","enrollment":65},{"nctId":"NCT06880744","phase":"PHASE3","title":"A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-17","conditions":"Ulcerative Colitis","enrollment":530},{"nctId":"NCT03196427","phase":"PHASE2","title":"Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-07-30","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":59},{"nctId":"NCT03819296","phase":"PHASE1","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-21","conditions":"Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8","enrollment":800},{"nctId":"NCT06856135","phase":"","title":"Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA","status":"AVAILABLE","sponsor":"Takeda","startDate":"","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":""},{"nctId":"NCT07123350","phase":"","title":"Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-10-16","conditions":"Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD), Ulcerative Colitis (UC)","enrollment":120},{"nctId":"NCT06257706","phase":"PHASE4","title":"VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease","status":"RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2024-08-07","conditions":"Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn","enrollment":304},{"nctId":"NCT04002180","phase":"","title":"Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2019-07-01","conditions":"Crohn's Disease","enrollment":335},{"nctId":"NCT04989907","phase":"","title":"A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-09-08","conditions":"Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative","enrollment":92},{"nctId":"NCT06570772","phase":"PHASE3","title":"Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio","status":"TERMINATED","sponsor":"Alvotech Swiss AG","startDate":"2024-09-23","conditions":"Ulcerative Colitis","enrollment":301},{"nctId":"NCT04407247","phase":"PHASE1, PHASE2","title":"Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-09","conditions":"Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm","enrollment":47},{"nctId":"NCT03221036","phase":"PHASE3","title":"Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis","status":"RECRUITING","sponsor":"Takeda","startDate":"2017-08-03","conditions":"Moderately to Severely Active Ulcerative Colitis","enrollment":402},{"nctId":"NCT06317220","phase":"PHASE2","title":"Vedolizumab for the Treatment of Collagenous Gastritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-12-03","conditions":"Collagenous Gastritis","enrollment":11},{"nctId":"NCT07273760","phase":"","title":"VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2023-07-16","conditions":"Ulcerative Colitis (UC), Crohn Disease (CD), Inflammatory Bowel Disease (IBD)","enrollment":150},{"nctId":"NCT05192863","phase":"","title":"A Study of Vedolizumab in Adults With Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-03-20","conditions":"Crohn's Disease","enrollment":72},{"nctId":"NCT05837897","phase":"PHASE3","title":"A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2023-06-16","conditions":"Crohn's Disease","enrollment":408},{"nctId":"NCT04779320","phase":"PHASE3","title":"A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2022-02-10","conditions":"Crohn's Disease (CD)","enrollment":120},{"nctId":"NCT04779307","phase":"PHASE3","title":"A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-10-19","conditions":"Colitis, Ulcerative","enrollment":121},{"nctId":"NCT06100289","phase":"PHASE3","title":"A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-01-22","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":70},{"nctId":"NCT03142321","phase":"PHASE4","title":"Defining Predictors of RT Response to Vedolizumab in IBD","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-06-08","conditions":"Crohn Disease of Small Intestine","enrollment":48},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT03824561","phase":"","title":"Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-02-01","conditions":"Ulcerative Colitis","enrollment":1110},{"nctId":"NCT05384080","phase":"","title":"A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-08-08","conditions":"Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis","enrollment":165},{"nctId":"NCT04738942","phase":"PHASE3","title":"A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2021-06-04","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":57},{"nctId":"NCT05481619","phase":"PHASE4","title":"Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-01-01","conditions":"Ulcerative Colitis","enrollment":30},{"nctId":"NCT06815003","phase":"PHASE2","title":"Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-04-18","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":35},{"nctId":"NCT05771155","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®","status":"ACTIVE_NOT_RECRUITING","sponsor":"Polpharma Biologics S.A.","startDate":"2023-07-24","conditions":"Ulcerative Colitis","enrollment":750},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT06227910","phase":"PHASE3","title":"A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-01-02","conditions":"Crohn's Disease","enrollment":396},{"nctId":"NCT06750731","phase":"","title":"Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention","status":"RECRUITING","sponsor":"Mercy Medical Center","startDate":"2025-05-05","conditions":"Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis","enrollment":200},{"nctId":"NCT05442567","phase":"PHASE3","title":"A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2023-05-16","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":240},{"nctId":"NCT02620046","phase":"PHASE3","title":"A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-04-15","conditions":"Colitis, Ulcerative, Crohn's Disease","enrollment":746},{"nctId":"NCT04804540","phase":"PHASE4","title":"A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-12-08","conditions":"Ulcerative Colitis, Crohn Disease","enrollment":150},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT04890262","phase":"","title":"A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World Practice","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-08-18","conditions":"Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative","enrollment":99},{"nctId":"NCT06604728","phase":"","title":"Effectiveness and Tolerance of IV vs SC Biological Drugs in Gastrointestinal Diseases","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-09-04","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT04959851","phase":"","title":"A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-12-02","conditions":"Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohns Disease","enrollment":185},{"nctId":"NCT05158517","phase":"","title":"VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2022-03-20","conditions":"Inflammatory Bowel Diseases","enrollment":349},{"nctId":"NCT04112212","phase":"PHASE1","title":"Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2020-11-04","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":38},{"nctId":"NCT04885920","phase":"","title":"A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-02-22","conditions":"Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative","enrollment":120},{"nctId":"NCT06337695","phase":"PHASE2, PHASE3","title":"VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2024-07-01","conditions":"Cancer, Cancer Metastatic","enrollment":298},{"nctId":"NCT02743806","phase":"PHASE4","title":"Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-08-01","conditions":"Colitis, Ulcerative, Crohn Disease","enrollment":331},{"nctId":"NCT05504915","phase":"","title":"Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Osijek","status":"COMPLETED","sponsor":"Osijek University Hospital","startDate":"2022-05-01","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative","enrollment":31},{"nctId":"NCT03029143","phase":"PHASE4","title":"Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-03-29","conditions":"Colitis, Ulcerative","enrollment":278},{"nctId":"NCT02764762","phase":"PHASE4","title":"Triple Combination Therapy in High Risk Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-18","conditions":"Crohn Disease","enrollment":55},{"nctId":"NCT03657160","phase":"PHASE3","title":"Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2019-02-06","conditions":"Hematopoietic Stem Cells","enrollment":343},{"nctId":"NCT03147859","phase":"PHASE2","title":"Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2017-11-01","conditions":"HIV-infection/AIDS","enrollment":10},{"nctId":"NCT03558152","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2018-10-26","conditions":"Ulcerative Colitis","enrollment":195},{"nctId":"NCT03234907","phase":"PHASE3","title":"Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-08-03","conditions":"Crohn's Disease","enrollment":215},{"nctId":"NCT02878083","phase":"NA","title":"Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2017-01-11","conditions":"ULCERATIVE COLITIS","enrollment":19},{"nctId":"NCT02862132","phase":"NA","title":"Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2017-01","conditions":"Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease","enrollment":142},{"nctId":"NCT02611830","phase":"PHASE3","title":"Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-12-18","conditions":"Colitis, Ulcerative","enrollment":383},{"nctId":"NCT02611817","phase":"PHASE3","title":"Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-01-04","conditions":"Crohn's Disease","enrollment":644},{"nctId":"NCT00790933","phase":"PHASE3","title":"An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-05-22","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":2243},{"nctId":"NCT02790138","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-10-12","conditions":"Pouchitis","enrollment":102},{"nctId":"NCT04919252","phase":"PHASE3","title":"Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-06-01","conditions":"Crohn's Disease and Ulcerative Colitis","enrollment":60},{"nctId":"NCT04469062","phase":"PHASE3","title":"A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","startDate":"2021-04-20","conditions":"Ulcerative Colitis","enrollment":""},{"nctId":"NCT02559713","phase":"PHASE4","title":"Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-11-29","conditions":"Colitis, Ulcerative, Crohn's Disease","enrollment":11},{"nctId":"NCT03138655","phase":"PHASE2","title":"Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-11-08","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":89},{"nctId":"NCT03802214","phase":"","title":"Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy","status":"TERMINATED","sponsor":"Stanford University","startDate":"2020-10-29","conditions":"Ulcerative Colitis","enrollment":1},{"nctId":"NCT02760615","phase":"PHASE4","title":"Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2016-11-01","conditions":"Colitis, Ulcerative, Crohn Disease","enrollment":""},{"nctId":"NCT02834754","phase":"PHASE2","title":"Vedolizumab Post Op Study","status":"WITHDRAWN","sponsor":"Marc Schwartz","startDate":"2018-12-01","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02497469","phase":"PHASE3","title":"An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-06-29","conditions":"Colitis, Ulcerative","enrollment":771},{"nctId":"NCT02038920","phase":"PHASE3","title":"Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-01-28","conditions":"Crohn's Disease","enrollment":157},{"nctId":"NCT02630966","phase":"PHASE4","title":"Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-08-10","conditions":"Crohn's Disease","enrollment":34},{"nctId":"NCT03329209","phase":"PHASE1","title":"A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-03-05","conditions":"Colitis, Ulcerative, Crohn Disease","enrollment":16},{"nctId":"NCT02728895","phase":"PHASE1","title":"Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-06-15","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":24},{"nctId":"NCT02993783","phase":"PHASE2","title":"A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2017-04-28","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":17},{"nctId":"NCT02324699","phase":"PHASE4","title":"Corticosteroids With Vedolizumab in Crohn's Disease","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2016-04","conditions":"Crohn's Disease","enrollment":1},{"nctId":"NCT02039505","phase":"PHASE3","title":"Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02-04","conditions":"Ulcerative Colitis","enrollment":292},{"nctId":"NCT02929316","phase":"PHASE2","title":"Vedolizumab Induction May Prevent Celiac Enteritis","status":"TERMINATED","sponsor":"AGA Clinical Research Associates, LLC","startDate":"2018-06-25","conditions":"Celiac Disease","enrollment":1},{"nctId":"NCT03309865","phase":"EARLY_PHASE1","title":"Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2017-12-25","conditions":"Ulcerative Colitis, Dietary Modification","enrollment":""},{"nctId":"NCT02425111","phase":"PHASE3","title":"Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03-30","conditions":"Crohn's Disease","enrollment":101},{"nctId":"NCT02820493","phase":"PHASE4","title":"Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF","status":"WITHDRAWN","sponsor":"Universita degli Studi di Genova","startDate":"2016-09","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT03035058","phase":"PHASE3","title":"Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2017-02","conditions":"Primary Sclerosing Cholangitis, Inflammatory Bowel Disease","enrollment":""},{"nctId":"NCT02163421","phase":"PHASE1","title":"Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-06","conditions":"Healthy","enrollment":48},{"nctId":"NCT02913508","phase":"PHASE2","title":"Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2014-04","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":""},{"nctId":"NCT01981616","phase":"PHASE1","title":"Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2011-09","conditions":"Inflammatory Bowel Disease","enrollment":127},{"nctId":"NCT00619489","phase":"PHASE2","title":"Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-12","conditions":"Ulcerative Colitis, Crohn's Disease","enrollment":72},{"nctId":"NCT01177228","phase":"PHASE2","title":"Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2007-05","conditions":"Ulcerative Colitis","enrollment":47},{"nctId":"NCT00655135","phase":"PHASE2","title":"Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2000-02","conditions":"Crohn's Disease","enrollment":185}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MLN0002SC","Entyvio","MLN0002","ENTYVIO","KYNTELES"],"phase":"marketed","status":"active","brandName":"Vedolizumab IV","genericName":"Vedolizumab IV","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on gut-homing lymphocytes, preventing their migration to the gastrointestinal tract. Used for Moderate to severe ulcerative colitis, Moderate to severe Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}